- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID-19: India likely to get US supplies of AstraZeneca vaccine in few weeks
![COVID-19: India likely to get US supplies of AstraZeneca vaccine in few weeks COVID-19: India likely to get US supplies of AstraZeneca vaccine in few weeks](https://medicaldialogues.in/h-upload/2020/09/04/750x450_133985-astrazeneca2.webp)
New York: The US is "looking at options" to ship millions of AstraZeneca vaccines to India but that can happen only after it clears federal safety review, the White House said on Monday. This process could take a few "weeks".
Approximately 10 million doses "could be released if and when FDA gives us concurrence, which could happen in the coming weeks", a senior Biden administration official told reporters at a briefing, where IANS was present.
As many as 60 million doses of the AstraZeneca vaccine are expected to be available for export in the coming months. An estimated additional 50 million doses of this vaccine are in various stages of production in the US, the White House confirmed.
The AstraZeneca vaccine has not yet been authorized by the US Food and Drug Administration.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story